Drug intelligence / Profile preview

JMEY-FS1

Development stage: Preclinical
Lead developer: Jianmin Pharmaceutical Group
Modality: Small Molecules

Overview

JMEY-FS1 is a pediatric drug candidate currently in the preclinical and CMC (Chemistry, Manufacturing, and Controls) stage of development by Jianmin Pharmaceutical Group. It is specifically being developed for the treatment of edema in children, as indicated by its inclusion in the company's 'JMEY' pediatric pipeline. Jianmin Pharmaceutical Group, through its Pediatric Research Institute, focuses on creating specialized formulations and treatments for the pediatric population.

Beyond the preview

Go deeper on JMEY-FS1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-FS1.

Explore the full profile